Skip to content
Riskpilot
← Back to search
Sign in
Get full access
Dragonfly Therapeutics CPH ApS
APS
In liquidation
Advertising protection
CVR 41557958
Baltorpvej 154, 2750
Ballerup
Forskning og eksperimentel udvikling indenfor bioteknologi
·
NACE 721100
Est. 2020 · 5 years old
16 employees
Monitor
Share
Denmark
/
Companies
/
Forskning og eksperimentel udvikling indenfor bioteknologi
/
Dragonfly Therapeutics CPH ApS
Overview
Financials
People & ownership
Related companies
Loading company…
People & ownership
Management
Actively employed in the business
Name
Role
Member since
Former (4)
GA
Gary Arthur Martell
Chief Executive Officer
Chief Executive Officer
2020 – 2022
EB
Esper Boel
Chief Executive Officer
Chief Executive Officer
2020 – 2020
DT
Dragonfly Therapeutics, Inc.
Founder
Founder
2020 – 2023
SS
Søren Sylvester Skjærbæk
Unofficial title
Unofficial title
2022 – 2023
Board of directors
Non-executive oversight
Name
Role
Member since
Former (1)
PA
Peter Andreas Nicolai Reumert Wagtmann
Board of Directors
Board of Directors
2020 – 2020
Shareholders
As of last annual report
Shareholder
Type
Ownership
Votes
Since
Dragonfly Therapeutics, Inc.
Individual
100%
100%
2020
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive.
Learn more
.
More on Dragonfly Therapeutics CPH ApS
Overview →
Headline figures, risk assessment and company summary
Financials & key figures →
Revenue, EBITDA, balance sheet and 5-year trend
Related companies →
Corporate hierarchy, parent and subsidiary network